<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00269867</url>
  </required_header>
  <id_info>
    <org_study_id>CR006259</org_study_id>
    <nct_id>NCT00269867</nct_id>
  </id_info>
  <brief_title>Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of infliximab (an
      anti-TNF chimeric monoclonal antibody [cA2]) in patients with active Rheumatoid Arthritis,
      despite methotrexate treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo-controlled, double-blinded, randomized clinical study to evaluate the
      safety and effectiveness of infliximab in patients with active Rheumatoid Arthritis, despite
      methotrexate treatment. Infliximab is an anti-TNF chimeric monoclonal antibody (cA2). The
      primary measures of effectiveness include the change from baseline in American College of
      Rheumatology (ACR20) response at week 30, and the change in the modified van der Heijde Sharp
      Score. The ACR20 Responder Index a composite of clinical, laboratory, and functional measures
      and the van der Heijde-Sharp (vdH-S) scoring method is a method of rating structural damage
      in patients..

      Patients will be treated with either infliximab or matching placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1997</start_date>
  <completion_date type="Actual">March 2000</completion_date>
  <primary_completion_date type="Actual">March 2000</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ACR20 response at week 30; Change in modified van der Heijde-Sharp Score</measure>
    <time_frame>Baseline and Week 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>up to Week 54</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">428</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab 3 mg/kg every 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab 3 mg/kg every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab 10 mg/kg every 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab 10 mg/kg every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab 3 mg/kg</intervention_name>
    <description>Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.</description>
    <arm_group_label>Infliximab 3 mg/kg every 8 weeks</arm_group_label>
    <arm_group_label>Infliximab 3 mg/kg every 4 weeks</arm_group_label>
    <other_name>anti-TNF chimeric monoclonal antibody (cA2)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab 10 mg/kg</intervention_name>
    <description>Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.</description>
    <arm_group_label>Infliximab 10 mg/kg every 8 weeks</arm_group_label>
    <arm_group_label>Infliximab 10 mg/kg every 4 weeks</arm_group_label>
    <other_name>anti-TNF chimeric monoclonal antibody (cA2)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with active Rheumatoid Arthritis despite treatment with methotrexate

          -  Diagnosed with Rheumatoid Arthritis at least 6 months prior to screening

          -  Having active disease at the time of screening and pre-infusion as defined by having
             at least 6 or more swollen joints and 6 or more tender joints

          -  Using methotrexate for at least 3 months prior to study enrollment

        Exclusion Criteria:

          -  Patients having any systemic inflammatory condition

          -  Having Lyme disease or a rheumatic disease other than Rheumatoid Arthritis

          -  Who have used Disease-Modifying Antirheumatic Drugs (DMARDs) other than methotrexate
             within 4 weeks prior to screening

          -  Who have used corticosteroids within 4 weeks prior to screening

          -  Having received previous administration of infliximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594-602.</citation>
    <PMID>11096166</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2005</study_first_submitted>
  <study_first_submitted_qc>December 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2005</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>infliximab</keyword>
  <keyword>methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

